REFERENCES
1. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012;60:1438-54.
2. Généreux P, Webb JG, Svensson LG, et al. PARTNER Trial Investigators. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol 2012;60:1043-52.
3. Arnold SV, Zhang Y, Baron SJ, et al. Impact of short-term complications on mortality and quality of life after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2019;12:362-9.
4. Ueshima D, Fovino LN, D'Amico G, Brener SJ, Esposito G, Tarantini G. Transcatheter versus surgical aortic valve replacement in low- and intermediate-risk patients: an updated systematic review and meta-analysis. Cardiovasc Interv Ther 2019;34:216-25.
5. Rahhab Z, Ramdat Misier K, El Faquir N, et al. Vascular complications after transfemoral transcatheter aortic valve implantation: a systematic review and meta-analysis. Structural Heart 2020;4:62-71.
6. Mack MJ, Leon MB, Thourani VH, et al. PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.
7. Popma JJ, Deeb GM, Yakubov SJ, et al. Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706-15.
8. Blanke P, Weir-McCall JR, Achenbach S, et al. Computed tomography imaging in the context of transcatheter aortic valve implantation (TAVI) / transcatheter aortic valve replacement (TAVR): an expert consensus document of the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr 2019;13:1-20.
9. Mangieri A, Laricchia A, Montalto C, et al. Patient selection, procedural planning and interventional guidance for transcatheter aortic valve intervention. Minerva Cardiol Angiol 2021;69:671-83.
10. Francone M, Budde RPJ, Bremerich J, et al. CT and MR imaging prior to transcatheter aortic valve implantation: standardisation of scanning protocols, measurements and reporting-a consensus document by the European Society of Cardiovascular Radiology (ESCR). Eur Radiol 2020;30:2627-50.
11. Junquera L, Urena M, Latib A, et al. Comparison of transfemoral versus transradial secondary access in transcatheter aortic valve replacement. Circ Cardiovasc Interv 2020;13:e008609.
12. Allende R, Urena M, Cordoba JG, et al. Impact of the use of transradial versus transfemoral approach as secondary access in transcatheter aortic valve implantation procedures. Am J Cardiol 2014;114:1729-34.
13. Di Mario C, Goodwin M, Ristalli F, et al. A prospective registry of intravascular lithotripsy-enabled vascular access for transfemoral transcatheter aortic valve replacement. JACC Cardiovasc Interv 2019;12:502-4.
14. Faroux L, Junquera L, Mohammadi S, et al. Femoral versus nonfemoral subclavian/carotid arterial access route for transcatheter aortic valve replacement: a systematic review and meta-analysis. J Am Heart Assoc 2020;9:e017460.
15. Beurtheret S, Karam N, Resseguier N, et al. Femoral versus nonfemoral peripheral access for transcatheter aortic valve replacement. J Am Coll Cardiol 2019;74:2728-39.
16. Dahle TG, Kaneko T, McCabe JM. Outcomes following subclavian and axillary artery access for transcatheter aortic valve replacement: Society of the Thoracic Surgeons/American College of Cardiology TVT Registry Report. JACC Cardiovasc Interv 2019;12:662-9.
17. Greenbaum AB, Babaliaros VC, Chen MY, et al. Transcaval access and closure for transcatheter aortic valve replacement: a prospective investigation. J Am Coll Cardiol 2017;69:511-21.
18. Lederman RJ, Babaliaros VC, Rogers T, et al. The fate of transcaval access tracts: 12-month results of the prospective NHLBI transcaval transcatheter aortic valve replacement study. JACC Cardiovasc Interv 2019;12:448-56.
19. Elbaz-Greener G, Zivkovic N, Arbel Y, Radhakrishnan S, Fremes SE, Wijeysundera HC. Use of two-dimensional ultrasonographically guided access to reduce access-related complications for transcatheter aortic valve replacement. Can J Cardiol 2017;33:918-24.
20. Mangieri A, Khokhar A, Giannini F, Colombo A. Transcatheter aortic valve replacement from a single vascular access: an ultra-minimalist approach. Clin Res Cardiol 2021;110:469-71.
21. Barbash IM, Barbanti M, Webb J, et al. Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation. Eur Heart J 2015;36:3370-9.
22. Dimitriadis Z, Scholtz W, Börgermann J, et al. Impact of closure devices on vascular complication and mortality rates in TAVI procedures. Int J Cardiol 2017;241:133-7.
23. Ott I, Shivaraju A, Schäffer NR, et al. Parallel suture technique with ProGlide: a novel method for management of vascular access during transcatheter aortic valve implantation (TAVI). EuroIntervention 2017;13:928-34.
24. Tarantini G. MANTA dedicated large-bore vessel closure device. Circ Cardiovasc Interv 2019;12:e008203.
25. Barbanti M, Capranzano P, Ohno Y, et al. Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. EuroIntervention 2015;11:690-7.
26. Berti S, Bedogni F, Giordano A, et al. Italian Society of Interventional Cardiology-GISE†. Efficacy and safety of ProGlide versus prostar XL vascular closure devices in transcatheter aortic valve replacement: the RISPEVA registry. J Am Heart Assoc 2020;9:e018042.
27. Van Mieghem NM, Latib A, van der Heyden J, et al. Percutaneous plug-based arteriotomy closure device for large-bore access: a multicenter prospective study. JACC Cardiovasc Interv 2017;10:613-9.
28. Wood DA, Krajcer Z, Sathananthan J, et al. SAFE MANTA Study Investigators. Pivotal clinical study to evaluate the safety and effectiveness of the MANTA percutaneous vascular closure device. Circ Cardiovasc Interv 2019;12:e007258.
29. Nuis RJ, Wood D, Kroon H, et al. Frequency, impact and predictors of access complications with plug-based large-bore arteriotomy closure - a patient level meta-analysis. Cardiovasc Revasc Med 2021; doi: 10.1016/j.carrev.2021.02.017.
30. Kroon HG, Tonino PAL, Savontaus M, et al. Dedicated plug based closure for large bore access - the MARVEL prospective registry. Catheter Cardiovasc Interv 2021;97:1270-8.
31. van Wiechen MP, Tchétché D, Ooms JF, et al. Suture- or plug-based large-bore arteriotomy closure: a pilot randomized controlled trial. JACC Cardiovasc Interv 2021;14:149-57.
32. Pasic M, Unbehaun A, Buz S, Drews T, Hetzer R. Annular rupture during transcatheter aortic valve replacement: classification, pathophysiology, diagnostics, treatment approaches, and prevention. JACC Cardiovasc Interv 2015;8:1-9.
33. Schymik G, Heimeshoff M, Bramlage P, et al. Ruptures of the device landing zone in patients undergoing transcatheter aortic valve implantation: an analysis of TAVI Karlsruhe (TAVIK) patients. Clin Res Cardiol 2014;103:912-20.
34. Aminian A, Lalmand J, Dolatabadi D. Late contained aortic root rupture and ventricular septal defect after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2013;81:E72-5.
35. Barbanti M, Yang TH, Rodès Cabau J, et al. Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement. Circulation 2013;128:244-53.
36. Hansson NC, Nørgaard BL, Barbanti M, et al. The impact of calcium volume and distribution in aortic root injury related to balloon-expandable transcatheter aortic valve replacement. J Cardiovasc Comput Tomogr 2015;9:382-92.
37. Barbanti M. Avoiding coronary occlusion and root rupture in TAVI - the role of pre-procedural imaging and prosthesis selection. Interv Cardiol 2015;10:94-7.
38. Tsuda M, Mizote I, Mukai T, Sakata Y. Aortic root rupture during balloon-expandable transcatheter aortic valve replacement in a patient without recognized risk factors for aortic root rupture: a case report. Eur Heart J Case Rep 2020;4:1-4.
39. Pignatelli A, Pestrichella V, Contegiacomo G, Navarese EP. Percutaneous treatment of aortic root rupture after transcatheter aortic valve replacement procedure. J Cardiovasc Med (Hagerstown) 2020;21:158-60.
40. Nagaraja V, Ratib K, Nolan J. Annular rupture successfully salvaged by valve-in-valve implantation. Structural Heart 2019;3:160-2.
41. Azarrafiy R, Albuquerque FN, Carrillo RG, Cohen MG. Coil embolization to successfully treat annular rupture during transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2018;92:1205-8.
42. Alkhouli M, Carpenter E, Tarabishy A, Sengupta P. Annular rupture during transcatheter aortic valve replacement: novel treatment with amplatzer vascular plugs. Eur Heart J 2018;39:714-5.
43. Conte SM, Kearney K, Jain P, et al. Plugging paravalvular leak in transcatheter aortic valves. JACC Case Rep 2019;1:696-702.
44. Takei M, Hasegawa T, Ohtsubo S, Takahashi T. Effusion in transverse sinus: a primary echocardiographic sign for aortic annular rupture in transcatheter aortic valve replacement. J Echocardiogr 2021;19:121-2.
45. Langer NB, Hamid NB, Nazif TM, et al. Injuries to the aorta, aortic annulus, and left ventricle during transcatheter aortic valve replacement: management and outcomes. Circ Cardiovasc Interv 2017;10:e004735.
46. Selhane D, Urena-alcazar M, Veugeois A, et al. Peri-procedural tamponade following TAVI: Incidence, predictors and impact on outcome. Arch Cardiovasc Dis Suppl 2019;11:70.
47. Hensey M, Daniels D, Wood D, Webb JG. Early experience with a purpose-designed temporary pacing guidewire for transcatheter valve implantation. EuroIntervention 2019;15:e508-9.
48. Makkar RR, Jilaihawi H, Chakravarty T, et al. Determinants and outcomes of acute transcatheter valve-in-valve therapy or embolization: a study of multiple valve implants in the U.S. PARTNER trial (Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve). J Am Coll Cardiol 2013;62:418-30.
49. Kim WK, Schäfer U, Tchetche D, et al. Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (TranscatheteR HeArt Valve EmboLization and Migration). Eur Heart J 2019;40:3156-65.
50. Eggebrecht H, Vaquerizo B, Moris C, et al. European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). Eur Heart J 2018;39:676-84.
51. Ibebuogu UN, Giri S, Bolorunduro O, et al. Review of reported causes of device embolization following trans-catheter aortic valve implantation. Am J Cardiol 2015;115:1767-72.
52. Nkomo VT, Suri RM, Pislaru SV, et al. Delayed transcatheter heart valve migration and failure. JACC Cardiovasc Imaging 2014;7:960-2.
53. Radu C, Raffoul R, Brochet E, Himbert D. Delayed migration of a transfemorally implanted aortic bioprosthesis. J Thorac Cardiovasc Surg 2012;143:e1-3.
54. Vendrik J, van den Boogert TPW, Koch KT, Baan J Jr. Balloon-expandable TAVR prosthesis dislocates into the ascending aorta. JACC Case Rep 2019;1:101-4.
55. Fournier S, Monney P, Roguelov C, et al. How should I treat an Edwards SAPIEN 3 aortic valve embolisation during a transaortic transcatheter aortic valve implantation? EuroIntervention 2017;13:495-8.
56. Ussia GP, Barbanti M, Ramondo A, et al. The valve-in-valve technique for treatment of aortic bioprosthesis malposition an analysis of incidence and 1-year clinical outcomes from the italian CoreValve registry. J Am Coll Cardiol 2011;57:1062-8.
57. Alkhouli M, Sievert H, Rihal CS. Device embolization in structural heart interventions: incidence, outcomes, and retrieval techniques. JACC Cardiovasc Interv 2019;12:113-26.
58. Tay EL, Gurvitch R, Wijeysinghe N, et al. Outcome of patients after transcatheter aortic valve embolization. JACC Cardiovasc Interv 2011;4:228-34.
59. Ribeiro HB, Nombela-Franco L, Urena M, et al. Coronary obstruction following transcatheter aortic valve implantation: a systematic review. JACC Cardiovasc Interv 2013;6:452-61.
60. Ribeiro HB, Webb JG, Makkar RR, et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol 2013;62:1552-62.
61. Dvir D, Leipsic J, Blanke P, et al. Coronary obstruction in transcatheter aortic valve-in-valve implantation: preprocedural evaluation, device selection, protection, and treatment. Circ Cardiovasc Interv 2015;8:e002079.
62. Jabbour RJ, Tanaka A, Finkelstein A, et al. Delayed coronary obstruction after transcatheter aortic valve replacement. J Am Coll Cardiol 2018;71:1513-24.
63. Ribeiro HB, Rodés-Cabau J, Blanke P, et al. Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. Eur Heart J 2018;39:687-95.
64. De Marco F, Casenghi M, Spagnolo P, et al. A patient-specific algorithm to achieve commissural alignment with Acurate Neo: the sextant technique. Catheter Cardiovasc Interv 2021;98:E847-54.
65. Tang GHL, Zaid S, Fuchs A, et al. Alignment of transcatheter aortic-valve neo-commissures (ALIGN TAVR): impact on final valve orientation and coronary artery overlap. JACC Cardiovasc Interv 2020;13:1030-42.
66. Kitamura M, Wilde J, Gohmann R, et al. Commissural alignment of the ACURATE neo valve in transcatheter aortic valve replacement. JACC Cardiovasc Interv 2021;14:1740-2.
67. Wong I, Bieliauskas G, De Backer O, Søndergaard L. Technical considerations for transcatheter aortic valve replacement with ACURATE neo2. JACC Cardiovasc Interv 2021;14:224-6.
68. Mercanti F, Rosseel L, Neylon A, et al. Chimney stenting for coronary occlusion during TAVR: insights from the chimney registry. JACC Cardiovasc Interv 2020;13:751-61.
69. Palmerini T, Chakravarty T, Saia F, et al. Coronary protection to prevent coronary obstruction during TAVR: a multicenter international registry. JACC Cardiovasc Interv 2020;13:739-47.
70. Abramowitz Y, Chakravarty T, Jilaihawi H, et al. Clinical impact of coronary protection during transcatheter aortic valve implantation: first reported series of patients. EuroIntervention 2015;11:572-81.
71. Pighi M, Lunardi M, Pesarini G, et al. Intravascular ultrasound assessment of coronary ostia following valve-in-valve transcatheter aortic valve implantation. EuroIntervention 2021;16:1148-51.
72. Khan JM, Greenbaum AB, Babaliaros VC, et al. The BASILICA trial: prospective multicenter investigation of intentional leaflet laceration to prevent TAVR coronary obstruction. JACC Cardiovasc Interv 2019;12:1240-52.
73. Lederman RJ, Babaliaros VC, Rogers T, et al. Preventing coronary obstruction during transcatheter aortic valve replacement: from computed tomography to BASILICA. JACC Cardiovasc Interv 2019;12:1197-216.
74. Khan JM, Dvir D, Greenbaum AB, et al. Transcatheter laceration of aortic leaflets to prevent coronary obstruction during transcatheter aortic valve replacement: concept to first-in-human. JACC Cardiovasc Interv 2018;11:677-89.
75. Komatsu I, Mackensen GB, Aldea GS, Reisman M, Dvir D. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction. Part 2: how to perform BASILICA. EuroIntervention 2019;15:55-66.
76. Komatsu I, Tang GHL, Leipsic J, et al. Distribution of C-arm projections in native and bioprosthetic aortic valves cusps: implication for BASILICA procedures. Catheter Cardiovasc Interv 2021;97:E580-7.
77. Tang GHL, Komatsu I, Tzemach L, et al. Risk of coronary obstruction and the need to perform BASILICA: the VIVID classification. EuroIntervention 2020;16:e757-9.
78. Khan JM, Babaliaros VC, Greenbaum AB, et al. Preventing coronary obstruction during transcatheter aortic valve replacement: results from the multicenter international BASILICA registry. JACC Cardiovasc Interv 2021;14:941-8.
79. Westermann D, Ludwig S, Kalbacher D, et al. Prevention of coronary obstruction in patients at risk undergoing transcatheter aortic valve implantation: the Hamburg BASILICA experience. Clin Res Cardiol 2021;110:1900-11.
80. Kitamura M, Majunke N, Holzhey D, et al. Systematic use of intentional leaflet laceration to prevent TAVI-induced coronary obstruction: feasibility and early clinical outcomes of the BASILICA technique. EuroIntervention 2020;16:682-90.
81. Makkar RR, Thourani VH, Mack MJ, et al. PARTNER 2 Investigators. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382:799-809.
82. Van Belle E, Vincent F, Labreuche J, et al. Balloon-expandable versus self-expanding transcatheter aortic valve replacement: a propensity-matched comparison from the FRANCE-TAVI registry. Circulation 2020;141:243-59.
83. Généreux P, Head SJ, Hahn R, et al. Paravalvular leak after transcatheter aortic valve replacement: the new Achilles’ heel? J Am Coll Cardiol 2013;61:1125-36.
84. Modolo R, Chang CC, Abdelghani M, et al. Quantitative assessment of acute regurgitation following TAVR: a multicenter pooled analysis of 2,258 valves. JACC Cardiovasc Interv 2020;13:1303-11.
85. Zoghbi WA, Asch FM, Bruce C, et al. Guidelines for the evaluation of valvular regurgitation after percutaneous valve repair or replacement: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Angiography and Interventions, Japanese Society of Echocardiography, and Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2019;32:431-75.
86. Akodad M, Lefèvre T. TAVI: simplification is the ultimate sophistication. Front Cardiovasc Med 2018;5:96.
87. Abdelghani M, Soliman OI, Schultz C, Vahanian A, Serruys PW. Adjudicating paravalvular leaks of transcatheter aortic valves: a critical appraisal. Eur Heart J 2016;37:2627-44.
88. Sinning JM, Hammerstingl C, Vasa-Nicotera M, et al. Aortic regurgitation index defines severity of peri-prosthetic regurgitation and predicts outcome in patients after transcatheter aortic valve implantation. J Am Coll Cardiol 2012;59:1134-41.
89. Chahine J, Kadri AN, Gajulapalli RD, et al. Outcomes of transcatheter aortic valve replacement in mixed aortic valve disease. JACC Cardiovasc Interv 2019;12:2299-306.
90. Bagur R, Webb JG, Nietlispach F, et al. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. Eur Heart J 2010;31:865-74.
91. Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T. All-Literature Investigation of Cardiovascular Evidence Group. Incidence, predictors, and prognosis of acute kidney injury after transcatheter aortic valve implantation: a summary of contemporary studies using Valve Academic Research Consortium definitions. Int J Cardiol 2013;168:1631-5.
92. Julien HM, Stebbins A, Vemulapalli S, et al. Incidence, predictors, and outcomes of acute kidney injury in patients undergoing transcatheter aortic valve replacement: insights from the Society of Thoracic Surgeons/American College of Cardiology National Cardiovascular Data Registry-Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv 2021;14:e010032.
93. Nuis RJ, Van Mieghem NM, Tzikas A, et al. Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2011;77:881-9.
94. Elhmidi Y, Bleiziffer S, Piazza N, et al. Incidence and predictors of acute kidney injury in patients undergoing transcatheter aortic valve implantation. Am Heart J 2011;161:735-9.
95. Kong WY, Yong G, Irish A. Incidence, risk factors and prognosis of acute kidney injury after transcatheter aortic valve implantation. Nephrology (Carlton) 2012;17:445-51.
96. Chandrasekhar J, Sartori S, Mehran R, et al. Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. Clin Res Cardiol 2021;110:649-57.
97. Yamamoto M, Hayashida K, Mouillet G, et al. Renal function-based contrast dosing predicts acute kidney injury following transcatheter aortic valve implantation. JACC Cardiovasc Interv 2013;6:479-86.
98. Giannini F, Latib A, Jabbour RJ, et al. The ratio of contrast volume to glomerular filtration rate predicts acute kidney injury and mortality after transcatheter aortic valve implantation. Cardiovasc Revasc Med 2017;18:349-55.
99. Barbanti M, Gulino S, Capranzano P, et al. Acute kidney injury with the RenalGuard system in patients undergoing transcatheter aortic valve replacement: the PROTECT-TAVI trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation). JACC Cardiovasc Interv 2015;8:1595-604.
100. Wang Y, Guo Y. RenalGuard system and conventional hydration for preventing contrast-associated acute kidney injury in patients undergoing cardiac interventional procedures: a systematic review and meta-analysis. Int J Cardiol 2021;333:83-9.
101. Suchá D, Kino A, Bogart K, et al. Effect of low contrast medium-dose CTA on device sizing and access vessel assessment for TAVR. Eur J Radiol 2020;124:108826.
102. Pulerwitz TC, Khalique OK, Nazif TN, et al. Very low intravenous contrast volume protocol for computed tomography angiography providing comprehensive cardiac and vascular assessment prior to transcatheter aortic valve replacement in patients with chronic kidney disease. J Cardiovasc Comput Tomogr 2016;10:316-21.
103. Cavallo AU, Patterson AJ, Thomas R, et al. Low dose contrast CT for transcatheter aortic valve replacement assessment: results from the prospective SPECTACULAR study (spectral CT assessment prior to TAVR). J Cardiovasc Comput Tomogr 2020;14:68-74.
104. Higuchi R, Tobaru T, Hagiya K, et al. Renoprotective transcatheter aortic valve implantation without contrast media. Int Heart J 2018;59:1469-72.
105. Castriota F, Nerla R, Micari A, Squeri A, Cremonesi A. Contrast-zero transcatheter aortic valve replacement for patients with severe renal dysfunction: a single-center experience. JACC Cardiovasc Interv 2018;11:820-2.
106. Huded CP, Tuzcu EM, Krishnaswamy A, et al. Association between transcatheter aortic valve replacement and early postprocedural stroke. JAMA 2019;321:2306-15.
107. Kapadia SR, Huded CP, Kodali SK, et al. PARTNER Trial Investigators. Stroke after surgical versus transfemoral transcatheter aortic valve replacement in the PARTNER trial. J Am Coll Cardiol 2018;72:2415-26.
108. Pagnesi M, Martino EA, Chiarito M, et al. Silent cerebral injury after transcatheter aortic valve implantation and the preventive role of embolic protection devices: a systematic review and meta-analysis. Int J Cardiol 2016;221:97-106.
109. Spaziano M, Francese DP, Leon MB, Généreux P. Imaging and functional testing to assess clinical and subclinical neurological events after transcatheter or surgical aortic valve replacement: a comprehensive review. J Am Coll Cardiol 2014;64:1950-63.
110. Kahlert P, Al-Rashid F, Döttger P, et al. Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study. Circulation 2012;126:1245-55.
111. Van Mieghem NM, Schipper ME, Ladich E, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation 2013;127:2194-201.
112. Stachon P, Kaier K, Heidt T, et al. The use and outcomes of cerebral protection devices for patients undergoing transfemoral transcatheter aortic valve replacement in clinical practice. JACC Cardiovasc Interv 2021;14:161-8.
113. Butala NM, Makkar R, Secemsky EA, et al. Cerebral embolic protection and outcomes of transcatheter aortic valve replacement: results from the transcatheter valve therapy registry. Circulation 2021;143:2229-40.
114. Latib A, Mangieri A, Vezzulli P, et al. First-in-man study evaluating the Emblok embolic protection system during transcatheter aortic valve replacement. JACC Cardiovasc Interv 2020;13:860-8.
115. Ahmad Y, Howard JP. Meta-analysis of usefulness of cerebral embolic protection during transcatheter aortic valve implantation. Am J Cardiol 2021;146:69-73.
116. Kapadia SR, Krishnaswamy A. Cerebral embolic protection in transcatheter aortic valve replacement: connecting intuition and proof. JACC Cardiovasc Interv 2021;14:169-71.
117. Bagur R, Solo K, Alghofaili S, et al. Cerebral embolic protection devices during transcatheter aortic valve implantation: systematic review and meta-analysis. Stroke 2017;48:1306-15.
118. Seeger J, Gonska B, Otto M, Rottbauer W, Wöhrle J. Cerebral embolic protection during transcatheter aortic valve replacement significantly reduces death and stroke compared with unprotected procedures. JACC Cardiovasc Interv 2017;10:2297-303.
119. Testa L, Latib A, Casenghi M, Gorla R, Colombo A, Bedogni F. Cerebral Protection during transcatheter aortic valve implantation: an updated systematic review and meta-analysis. J Am Heart Assoc 2018;7:e008463.
120. Coughlan JJ, Fleck R, O’Connor C, Crean P. Mechanical thrombectomy of embolised native aortic valve post-TAVI. BMJ Case Rep 2017;2017:bcr2016218787.
121. D’Anna L, Demir O, Banerjee S, Malik I. Intravenous thrombolysis and mechanical thrombectomy in patients with stroke after TAVI: a report of two cases. J Stroke Cerebrovasc Dis 2019;28:104277.
122. Muntané-Carol G, Urena M, Munoz-Garcia A, et al. Late cerebrovascular events following transcatheter aortic valve replacement. JACC Cardiovasc Interv 2020;13:872-81.
123. Mangieri A, Montalto C, Poletti E, et al. Thrombotic versus bleeding risk after transcatheter aortic valve replacement: JACC review topic of the week. J Am Coll Cardiol 2019;74:2088-101.
124. Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-91.
125. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252-89.
126. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017;389:2383-92.
127. Backer O, Dangas GD, Jilaihawi H, et al; GALILEO-4D Investigators. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med 2020;382:130-9.
128. Rosendael PJ, Delgado V, Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J 2018;39:2003-13.
129. Sammour Y, Krishnaswamy A, Kumar A, et al. Incidence, predictors, and implications of permanent pacemaker requirement after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2021;14:115-34.
130. Auffret V, Puri R, Urena M, et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives. Circulation 2017;136:1049-69.
131. Mangieri A, Lanzillo G, Bertoldi L, et al. Predictors of advanced conduction disturbances requiring a late (≥48 h) permanent pacemaker following transcatheter aortic valve replacement. JACC Cardiovasc Interv 2018;11:1519-26.
132. Mauri V, Reimann A, Stern D, et al. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv 2016;9:2200-9.
133. Latsios G, Gerckens U, Buellesfeld L, et al. “Device landing zone” calcification, assessed by MSCT, as a predictive factor for pacemaker implantation after TAVI. Catheter Cardiovasc Interv 2010;76:431-9.
134. Krishnaswamy A, Sammour Y, Mangieri A, et al. The utility of rapid atrial pacing immediately post-TAVR to predict the need for pacemaker implantation. JACC Cardiovasc Interv 2020;13:1046-54.
135. Möllmann H, Hengstenberg C, Hilker M, et al. Real-world experience using the ACURATE neo prosthesis: 30-day outcomes of 1,000 patients enrolled in the SAVI TF registry. EuroIntervention 2018;13:e1764-70.
136. Tang GHL, Zaid S, Michev I, et al. “Cusp-Overlap” view simplifies fluoroscopy-guided implantation of self-expanding valve in transcatheter aortic valve replacement. JACC Cardiovasc Interv 2018;11:1663-5.
137. Mendiz OA, Noč M, Fava CM, et al. Impact of cusp-overlap view for TAVR with self-expandable valves on 30-day conduction disturbances. J Interv Cardiol 2021;2021:9991528.
138. Sammour Y, Banerjee K, Kumar A, et al. Systematic approach to high implantation of SAPIEN-3 valve achieves a lower rate of conduction abnormalities including pacemaker implantation. Circ Cardiovasc Interv 2021;14:e009407.
139. Jilaihawi H, Zhao Z, Du R, et al. Minimizing permanent pacemaker following repositionable self-expanding transcatheter aortic valve replacement. JACC Cardiovasc Interv 2019;12:1796-807.
